id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-338741-gy3ovkrt	Sethi, Atin	Evaluation of Current Therapies for COVID-19 Treatment	2020-07-22		.txt	text/plain	5580	333	47	No survival benefit for those not requiring respiratory support [22] Convalescent plasma n = 10 severely ill patients Treatment: 200 mL IV In all 10 patients, fever, cough, shortness of breath, and chest pain disappeared or largely improved within 1-3 days of therapy initiation [23] In vitro study determining the activity of convalescent plasma from a recovered SARS-1 patient against SARS-CoV-2 Although the focus of this study was not to explore the efficacy of hydroxychloroquine/azithromycin, it outlines the importance of appropriate risk-benefit analysis while treating patients with COVID-19. This randomized control trial [10] of 199 patients explored the efficacy of lopinavir-ritonavir in hospitalized COVID-19 patients with relatively mild respiratory illness. Efficacy of hydroxychloroquine in patients with COVID-19: Results of a randomized clinical trial Clinical and microbiological effect of a combination of hydroxychloroquine and azithromycin in 80 COVID-19 patients with at least a six-day follow up: A pilot observational study	./cache/cord-338741-gy3ovkrt.txt	./txt/cord-338741-gy3ovkrt.txt